#151871

Anti-DRAM1 [M3-P4B4]

Cat. #151871

Anti-DRAM1 [M3-P4B4]

Cat. #: 151871

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Damage Regulated Autophagy Modulator 1 (DRAM1)

Class: Monoclonal

Application: ELISA ; IHC ; IF ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-DRAM1 [M3-P4B4]
  • Cancer: Digestive/Gastrointestinal cancer
  • Cancers detailed: Colorectal
  • Research fields: Apoptosis and autophagy;Cancer;Cell biology;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
  • Clone: M3-P4B4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; IF ; WB
  • Description: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.
  • Immunogen: Peptide Sequence - EKDYVYHVVS (amino acids 192 - 201)
  • Isotype: IgG1
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: ELISA- Peptide immunogenWestern Blot- Hela cell extract (cytoplasmic fraction)IF- Hela CellsIHC- Human hepatocellular carcinoma

Target Details

  • Target: Damage Regulated Autophagy Modulator 1 (DRAM1)
  • Tissue cell line specificity: ELISA- Peptide immunogenWestern Blot- Hela cell extract (cytoplasmic fraction)IF- Hela CellsIHC- Human hepatocellular carcinoma
  • Target background: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.

Applications

  • Application: ELISA ; IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.
  • The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.